Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins
Rattachement africain : no. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
High-grade serous ovarian carcinoma (HGSOC) is the most common and deadliest ovarian cancer subtype. Despite advances in treatment, the overall prognosis remains poor. Regardless of efforts to develop biomarkers to predict surgical outcome and recurrence risk and resistance, reproducible indicators are scarce. Exploring the complex tumor heterogeneity, serum profiling of metabolites and lipoprotein subfractions that reflect both systemic and local biological processes were utilized. Furthermore, the overall impact on the patient from the tumor and the treatment was investigated. The aim was to characterize the systemic metabolic effects of primary treatment in patients with advanced HGSOC. In total 28 metabolites and 112 lipoproteins were analyzed by nuclear magnetic resonance (NMR) spectroscopy in longitudinal serum samples (n = 112) from patients with advanced HGSOC (n = 24) from the IMPACT trial with linear mixed effect models and repeated measures ANOVA simultaneous component analysis. The serum profiling revealed treatment-induced changes in both lipoprotein subfractions and circulating metabolites. The development of a more atherogenic lipid profile throughout the treatment, which was more evident in patients with short time to recurrence, indicates an enhanced systemic inflammation and increased risk of cardiovascular disease after treatment. The findings suggest that treatment-induced changes in the metabolome reflect mechanisms behind the diversity in disease-related outcomes.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Primary Treatment Effects for High-Grade Serous Ovarian Carcinoma Evaluated by Changes in Serum Metabolites and Lipoproteins
- Date Crossref
- 12/03/2023
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Stavanger University Hospital Department of Obstetrics and Gynecology pays non établi dans la noticeÉtablissement de santé
-
University of Bergen Department of Clinical Science pays non établi dans la noticeUniversité ou école supérieure
-
Norwegian University of Science and Technology Department of Clinical and Molecular Medicine pays non établi dans la noticeUniversité ou école supérieure
-
St Olav's University Hospital pays non établi dans la noticeÉtablissement de santé
-
Haukeland University Hospital Department of Obstetrics and Gynecology pays non établi dans la noticeÉtablissement de santé
-
Trondheim University Hospital Department of Gynecology and Obstetrics pays non établi dans la noticeUniversité ou école supérieure
Department of Obstetrics and Gynecology — Stavanger University Hospital, Department of Clinical Science — University of Bergen et Department of Clinical and Molecular Medicine — Norwegian University of Science and Technology, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.